Pharma

Your Article Summary

See Latest Articles

Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 2009
Mylan, 07/31/09

Mylan's Chairman and CEO Robert J. Coury commented: "This was yet another successful quarter on many fronts for Mylan as, across the board, we delivered another quarter of financial performance that exceeded our expectations. Our powerful and integrated global platform enabled each of our businesses to generate year–over–year quarterly revenue growth on a constant currency basis and to deliver additional operational efficiencies as well. In addition, we took an important initial step in one of our targeted areas of future growth by entering into a collaborative agreement with Biocon in the area of generic biologics."

Today in Financial Reports...keeping you current

Receive free subspecialty "5-minute updates" via email

VA Re-Ups with QuadraMed
HealthDataManagement, 12/18/09

Bristol-Myers Squibb Sets Exchange Ratio of 0.6313 for the Exchange Offer
Bristol Myers-Squibb Company, 12/17/09

Abbott Declares 344th Consecutive Quarterly Dividend
Abbott, 12/15/09

 See all of Financial Reports